A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 400,000 shares of OLMA stock, worth $2.33 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
400,000
Previous 325,000 23.08%
Holding current value
$2.33 Million
Previous $3.52 Million 35.84%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.41 - $16.46 $780,750 - $1.23 Million
75,000 Added 23.08%
400,000 $4.78 Million
Q2 2024

Aug 14, 2024

SELL
$8.73 - $13.99 $1.18 Million - $1.89 Million
-135,000 Reduced 29.35%
325,000 $3.52 Million
Q1 2024

May 15, 2024

SELL
$10.95 - $16.62 $438,000 - $664,800
-40,000 Reduced 8.0%
460,000 $5.21 Million
Q4 2023

Feb 14, 2024

BUY
$10.53 - $17.14 $1.17 Million - $1.9 Million
111,018 Added 28.54%
500,000 $7.02 Million
Q3 2023

Nov 14, 2023

BUY
$8.19 - $12.98 $1.29 Million - $2.04 Million
157,549 Added 68.08%
388,982 $4.8 Million
Q2 2023

Aug 14, 2023

SELL
$3.22 - $9.65 $607,185 - $1.82 Million
-188,567 Reduced 44.9%
231,433 $2.09 Million
Q3 2022

Nov 14, 2022

SELL
$2.72 - $5.88 $217,600 - $470,400
-80,000 Reduced 16.0%
420,000 $1.16 Million
Q2 2022

Aug 15, 2022

BUY
$2.04 - $4.61 $838,854 - $1.9 Million
411,203 Added 463.08%
500,000 $2.04 Million
Q1 2022

May 16, 2022

BUY
$3.89 - $9.43 $345,420 - $837,355
88,797 New
88,797 $378,000
Q3 2021

Nov 15, 2021

SELL
$22.96 - $30.13 $5.17 Million - $6.78 Million
-225,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$21.15 - $36.14 $4.76 Million - $8.13 Million
225,000 New
225,000 $6.3 Million

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $236M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.